Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results, demonstrate breakthrough HER2-targeted pan-tumor
Pemigatinib generated efficacy and tolerability in previously treated patients with advanced/metastatic or unresectable solid tumors harboring activating FGFR mutations or fusions/rearrangements, including cholangiocarcinoma, central nervous system tumors, gynecologic tumors, and pancreatic cancer.
/PRNewswire/ Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced that it has added.
/CNW/ - Soricimed Biopharma Inc., ("Soricimed" or "the Company"), a clinical stage company focused on the development and commercialization of first-in-class.